Predictors of blood pressure response in the SYMPLICITY HTN-3 trial

European Heart Journal

Volumn 36, Issue 4, 2015, Pages 219-227

  Kandzari, David E ^a   Bhatt, Deepak L ^b   Brar, Sandeep ^c   Devireddy, Chandan M ^d   Esler, Murray ^e   Fahy, Martin ^c   Flack, John M ^f   Katzen, Barry T ^g   Lea, Janice ^d   Lee, David P ^h   Leon, Martin B ⁱ   Ma, Adrian ^h   Massaro, Joseph ^j   Mauri, Laura ^b,j   Oparil, Suzanne ^k   O'Neill, William W ^l   Patel, Manesh R ^m   Rocha Singh, Krishna ⁿ   Sobotka, Paul A ^o   Svetkey, Laura ^m   Townsend, Raymond R ^p   Bakris, George L ^q   more..

^a PIEDMONT HEART INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDTRONIC INC   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MONASH UNIVERSITY   (Australia)

^f WAYNE STATE UNIVERSITY   (United States)

^g BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NewYork Presbyterian Hospital   (United States)

^j HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l HENRY FORD HOSPITAL   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ Prairie Heart Institute   (United States)

^o OHIO STATE UNIVERSITY   (United States)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

^q UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

Renal denervation; Resistant hypertension; SYMPLICITY

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYDRALAZINE; MINOXIDIL; RESERPINE;

ABLATION THERAPY; ADULT; AFRICAN AMERICAN; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; DRUG SUBSTITUTION; DRUG USE; ENERGY; HEART RATE; HUMAN; KIDNEY DENERVATION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SAFETY; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CATHETER ABLATION; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; HYPERTENSION; INNERVATION; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SYMPATHECTOMY; TREATMENT OUTCOME;

ADULT; BLOOD PRESSURE; CATHETER ABLATION; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84924426046     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu441     Document Type: Article

References (29)

1. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1, 266 cases. J Am Med Assoc 1953; 152: 1501-1504.
2. Longland CJ, Gibb WE. Sympathectomy in the treatment of benign and malignant hypertension; a review of 76 patients. Br J Surg 1954; 41: 382-392.
3. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 1988; 11: 3-20.
4. Esler M, Lambert G, Jennings G, Turner A, Kaye D. Central and peripheral norepinephrine kinetics in heart failure, coronary artery disease, and hypertension. Adv Pharmacol 1998; 42: 650-653.
5. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010; 298: R245-R253.
6. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA; for the Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012; 126: 2976-2982.
7. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629.
8. Mahfoud F, Mancia G, Schlaich MP, Narkiewics K, Ruilope L, Schmieder R, Böhm M. Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY registry. Presented at the European Society of Cardiology, Barcelona 2014; p62.
9. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Böhm M, European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-2157.
10. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-An interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
11. Bhatt DL, Kandzari DE, ONeill WW, DAgostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators.Acontrolled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
12. Kandzari DE, Bhatt DL, Sobotka PA, ONeill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 trial. Clin Cardiol 2012; 35: 528-535.
13. Rosenbaum PR, Rubin D. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Statist 1985; 39: 33-38.
14. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774.
15. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
16. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-472.
17. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment, and control-continued disparities in adults: United States, 2005-2006. NCHS Data Brief 2008: 1-8.
18. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001; 23: 1999-2010.
19. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56: 824-830.
20. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423-1431.
21. Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31: 2094-2102.
22. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension 2010; 55: 1217-1223.
23. Cubeddu LX, Aranda J, Singh B, Klein M, Brachfeld J, Freis E, Roman J, Eades T. Acomparison of verapamil and propranolol for the initial treatment of hypertension. Racial differences in response. JAMA 1986; 256: 2214-2221.
24. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Groupon AntihypertensiveAgents. N Engl J Med 1993; 328: 914-921.
25. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensinconverting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351-1357.
26. Esler M. Illusions of truths in the SymplicityHTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014; 8: 593-598.
27. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77: 75-197.
28. Hering D, Marusic P, Walton AS, Lambert EA, Krum H, Narkiewicz K, Lambert GW, Esler MD, Schlaich MP. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension 2014; 64: 118-124.
29. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-Arterial renal nerves in man. J Am Coll Cardiol 2014; 64: 635-643.